Poster Altan Goktas


To evaluate the effect of intravitreal ranibizumab injection on cardiac ischemic parameters and vascular endothelial function.


This observational, prospective case series included a total of 48 patients (23 patients with age-related macular degeneration and 25 patients with diabetic macular edema). All participants received intravitreal injections of 0.5 mg ranibizumab. Cardiac ischemic parameters including total creatinine kinase, creatinine kinase-MB and electrocardiography and endothelial function measured with flow-mediated dilatation of the brachial artery with two-dimensional and Doppler ultrasonography were evaluated before and 1day and 1 month after the injection.


Mean age of the patients (28 female and 20 male) was 61 ±4.1 (53-72). Cardiac ischemic parameters and vascular endothelial function did not show statistically significant differences across the time points.


Besides its antiangiogenic action, ranibizumab was shown to display distinct effects on endothelial cells in in-vitro studies. On the contrary, we did not observe any significant change in vascular endothelial function. Furthermore, knowledge of the effect of ranibizumab on cardiovascular system was generally recruited from the retrospective studies. So our prospective study confirms that intravitreal injections ranibizumab were not associated with significant risks of myocardial ischemia.